Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Verified site
Meldola, Italy
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This clinical trial is studying treatment for patients with stage IV colorectal cancer who have undergone surgery to remove their tumors. The study uses two treatments: DC-VACCINE_IRSTIRCCS, which is made from the patient's own cells (specifically dendritic cells loaded with tumor material), and Proleukin (also known as aldesleukin). Dendritic cells are important immune system cells that help the body recognize and fight cancer cells.
The purpose of this study is to evaluate how safe the treatment is and how well it stimulates the immune system to fight against cancer cells. The treatment involves taking some of the patient's tumor tissue removed during surgery and using it to create a personalized vaccine. This vaccine is then injected under the skin along with Proleukin, which helps strengthen the immune response.
The treatment period lasts up to 6 months. The vaccine is given through intradermal injection (into the skin), while Proleukin is administered through subcutaneous injection (under the skin). During the study, doctors will monitor patients' immune responses and check for any side effects from the treatment. This is a phase II study, which means it follows initial safety testing of the treatment in humans.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
10 criteria
14 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
RecruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a personalized treatment made from the patient's own immune cells. These cells are collected from the patient's blood, specially processed in a laboratory, and then loaded with proteins from the patient's own tumor tissue. When injected back into the patient, these modified cells help train the immune system to recognize and fight against remaining cancer cells. This type of immunotherapy is designed to work specifically for each individual patient's cancer.
is material created from the patient's own tumor tissue that has been removed during surgery. The tumor tissue is processed into a form that can be combined with dendritic cells to create the personalized vaccine. This ensures that the immune response is targeted specifically to the patient's unique cancer characteristics.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.